Literature DB >> 31276911

The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.

Chuan Qin1, Bo Chen1, Ran Tao1, Man Chen1, Xue Ma1, Ke Shang1, Long-Jun Wu2, Wei Wang1, Bi-Tao Bu3, Dai-Shi Tian4.   

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) refers to a range of autoimmune inflammatory demyelinating diseases affecting the optic nerves, spinal cord, and periependymal regions of the brain. Classical NMOSD is characterized by the presentation of autoantibodies against the water channel aquaporin-4 (AQP4). However, a subset of patients fulfilling the clinical criteria for NMOSD is negative for AQP4-IgG but positive for autoantibodies against myelin oligodendrocyte glycoprotein (MOG); these patients are associated with different clinical manifestations and pathogenesis.
METHODS: Patients who received a first diagnosis of NMOSD were reviewed retrospectively between April 2015 and December 2018. Patients were classified according to the presence of AQP4-IgG and MOG-IgG in serum and/or cerebrospinal fluid. Clinical characteristics, magnetic resonance imaging findings, disease severity, and serum C3 and C4 levels at the first episode were compared between the groups.
RESULTS: The NMOSD patients with AQP4-IgG and MOG-IgG demonstrated specific, differential clinical features. The AQP4-IgG group featured more women, the presentation of transverse myelitis attacks and simultaneous occurrence of optic neuritis and transverse myelitis were more common, and intrathecal synthesis was more evident. The MOG-IgG group featured younger patients, more acute disseminated encephalomyelitis (ADEM) or ADEM-like attacks, more frequent cerebrospinal fluid pleocytosis, and a better overall outcome. C3 levels were significantly lower in AQP4-IgG-positive patients and higher in MOG-IgG-positive patients relative to healthy controls. C4 levels were significantly lower in the AQP4-IgG-positive NMOSD group when compared to both MOG-IgG-positive patients and controls. C3 and C4 were then combined in a receiver operating characteristic model. The area under the curve of the model was calculated to differentiate the AQP4-IgG-positive group from the MOG-IgG-positive group was 0.787, which was considered moderately predictive.
CONCLUSION: The combination of C3 and C4 could assist in the differential diagnosis of AQP4-IgG-positive NMOSD from MOG-IgG-positive NMOSD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AQP4; Complement; MOG; NMOSD

Mesh:

Substances:

Year:  2019        PMID: 31276911     DOI: 10.1016/j.msard.2019.06.035

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  5 in total

1.  Dual spinal cord injury: a case of acute traumatic T9 AIS A spinal cord injury complicated by transverse myelitis.

Authors:  Tyler M Estes; Esther Tompkins; Noel E Pristas; Rani H Lindberg
Journal:  Spinal Cord Ser Cases       Date:  2020-08-24

2.  PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia.

Authors:  C Restrepo-Aristizábal; L M Giraldo; Y M Giraldo; A M Pino-Pérez; F Álvarez-Gómez; C A Franco; J V Tobón; J L Ascencio; M I Zuluaga
Journal:  Heliyon       Date:  2021-04-17

Review 3.  Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease.

Authors:  Alessandro Dinoto; Elia Sechi; Eoin P Flanagan; Sergio Ferrari; Paolo Solla; Sara Mariotto; John J Chen
Journal:  Front Neurol       Date:  2022-03-23       Impact factor: 4.003

4.  Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.

Authors:  Liuyu Lin; Yuqing Wu; Hailun Hang; Jie Lu; Yuanliang Ding
Journal:  Front Immunol       Date:  2022-07-11       Impact factor: 8.786

5.  Relationship between the Clinical Characteristics in Patients with Neuromyelitis Optica Spectrum Disorders and Clinical Immune Indicators: A Retrospective Study.

Authors:  Linjun Cai; Ziyan Shi; Hongxi Chen; Qin Du; Ying Zhang; Zhengyang Zhao; Jiancheng Wang; Yanling Lang; Lingyao Kong; Hongyu Zhou
Journal:  Brain Sci       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.